TBPH RSI Chart
Last 7 days
-0.8%
Last 30 days
-2.3%
Last 90 days
5.7%
Trailing 12 Months
-14.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 54.4M | 0 | 0 | 0 |
2023 | 51.3M | 51.3M | 54.5M | 0 |
2022 | 54.3M | 52.4M | 52.0M | 51.3M |
2021 | 66.3M | 64.2M | 59.1M | 55.3M |
2020 | 87.9M | 76.8M | 82.6M | 71.9M |
2019 | 57.4M | 60.1M | 59.7M | 73.4M |
2018 | 20.6M | 40.6M | 49.1M | 60.4M |
2017 | 33.3M | 31.4M | 16.6M | 15.4M |
2016 | 40.1M | 38.5M | 46.8M | 48.6M |
2015 | 31.1M | 35.3M | 39.7M | 42.1M |
2014 | 1.1M | 4.1M | 10.4M | 11.7M |
2013 | 104.3M | 78.5M | 52.7M | 26.9M |
2012 | 0 | 0 | 0 | 130.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 08, 2024 | broshy eran | acquired | - | - | 10,537 | - |
May 08, 2024 | o'connor donal | acquired | - | - | 10,537 | - |
May 08, 2024 | mitchell dean j | acquired | - | - | 10,537 | - |
May 08, 2024 | smaldone alsup laurie | acquired | - | - | 10,537 | - |
May 08, 2024 | grant jeremy t | acquired | - | - | 10,537 | - |
May 08, 2024 | gray susannah | acquired | - | - | 10,537 | - |
May 08, 2024 | pakianathan deepika | acquired | - | - | 10,537 | - |
May 01, 2024 | samaha eli | bought | 13,117,300 | 8.75 | 1,499,120 | - |
Apr 02, 2024 | farnum rhonda | acquired | - | - | 37,500 | svp, comm & medical affairs |
Apr 02, 2024 | winningham rick e | acquired | - | - | 300,000 | chief executive officer |
Which funds bought or sold TBPH recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -17.1 | -176,424 | 344,932 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -90.95 | -3,874,390 | 301,464 | -% |
May 15, 2024 | JACOBS LEVY EQUITY MANAGEMENT, INC | added | 41.61 | 576,215 | 5,005,000 | 0.02% |
May 15, 2024 | PDT Partners, LLC | added | 104 | 231,523 | 595,958 | 0.06% |
May 15, 2024 | Atom Investors LP | new | - | 103,837 | 103,837 | 0.01% |
May 15, 2024 | Steward Partners Investment Advisory, LLC | new | - | 13,455 | 13,455 | -% |
May 15, 2024 | Squarepoint Ops LLC | sold off | -100 | -585,087 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -98.29 | -258,704 | 3,570 | -% |
May 15, 2024 | Madison Avenue Partners, LP | unchanged | - | -15,917,800 | 62,899,700 | 10.15% |
May 15, 2024 | PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO | unchanged | - | -25,000 | 97,000 | -% |
Unveiling Theravance Biopharma Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Theravance Biopharma Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Theravance Biopharma Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -7.6% | 14,503,000 | 15,693,000 | 13,749,000 | 10,417,000 | 14,649,000 | 12,451,000 | 11,750,500 | 11,050,000 | 13,196,000 | 14,946,000 | 13,194,000 | 12,914,000 | 14,257,000 | 18,730,000 | 18,257,000 | 15,008,000 | 19,862,000 | 29,499,000 | 12,427,000 | 26,150,000 | 5,338,000 |
Operating Expenses | 5.1% | 25,710,000 | 24,453,000 | 29,872,000 | 35,329,000 | 32,081,000 | 21,595,000 | - | 37,929,000 | 51,698,000 | 71,113,000 | 66,809,000 | 77,024,000 | 98,149,000 | 95,220,000 | 94,872,000 | 87,184,000 | 92,338,000 | 100,071,000 | 77,628,000 | 68,626,000 | 79,004,000 |
S&GA Expenses | 3.7% | 16,742,000 | 16,142,000 | 19,278,000 | 19,183,000 | 16,732,000 | 16,277,000 | -15,890,000 | 16,222,000 | 17,842,000 | 21,516,000 | 21,299,000 | 25,931,000 | 30,550,000 | 29,925,000 | 27,501,000 | 24,780,000 | 26,325,000 | 33,046,000 | 25,622,000 | 22,227,000 | 25,186,000 |
R&D Expenses | 7.9% | 8,968,000 | 8,311,000 | 9,425,000 | 14,572,000 | 15,348,000 | 9,867,000 | - | 14,924,000 | 23,253,000 | 31,226,000 | 43,739,000 | 51,093,000 | 67,599,000 | 65,165,000 | 67,371,000 | 62,404,000 | 66,013,000 | 67,025,000 | 52,006,000 | 46,399,000 | 53,818,000 |
EBITDA Margin | 40.5% | -0.58 | -0.97 | -1.18 | -1.31 | -1.62 | -2.79 | -3.53 | -3.51 | -3.76 | -4.23 | -4.52 | -4.29 | - | - | - | - | - | - | - | - | - |
Interest Expenses | 3.3% | 629,000 | 609,000 | 568,000 | 550,000 | 550,000 | 1,545,000 | - | 2,137,000 | 2,137,000 | -7,468,500 | 2,136,000 | 11,612,000 | 11,873,000 | -24,358,000 | 11,573,000 | 11,391,000 | 9,941,000 | 8,035,000 | 8,068,000 | 7,901,000 | 7,858,000 |
Income Taxes | -7.1% | 1,300,000 | 1,400,000 | 1,500,000 | -395,000 | -3,000 | -507,000 | - | -5,000 | 524,000 | 1,756,000 | -7,000 | -220,000 | 227,000 | -8,799,000 | 93,000 | 39,000 | 147,000 | 49,000 | -5,552,000 | 201,000 | 80,000 |
Earnings Before Taxes | -37.2% | -10,402,000 | -7,583,000 | -14,187,000 | -22,483,000 | -14,259,000 | -16,023,000 | - | -22,798,000 | -39,735,000 | -67,597,000 | -55,917,000 | -52,625,000 | -79,452,000 | -84,039,000 | -73,550,000 | -62,848,000 | -82,906,000 | -65,557,000 | -63,983,000 | -39,637,000 | -72,500,000 |
EBT Margin | 36.3% | -0.68 | -1.07 | -1.31 | -1.47 | -1.81 | -2.83 | -3.58 | -3.55 | -3.98 | -4.62 | -4.60 | -4.51 | - | - | - | - | - | - | - | - | - |
Net Income | -30.3% | -11,664,000 | -8,950,000 | -15,645,000 | -22,088,000 | -10,362,000 | 916,631,000 | 31,629,000 | -8,191,000 | -25,946,000 | -32,034,000 | -35,308,000 | -52,405,000 | -79,679,000 | -58,434,000 | -73,643,000 | -62,887,000 | -83,053,000 | -65,606,000 | -58,431,000 | -39,838,000 | -72,580,000 |
Net Income Margin | 21.3% | -0.82 | -1.05 | 16.94 | 17.85 | 18.11 | 17.68 | -0.66 | -1.94 | -2.69 | -3.61 | -3.82 | -4.12 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 46.9% | -1,660,000 | -3,124,000 | -13,074,000 | -11,859,000 | -124,693,000 | -22,775,000 | -15,368,000 | -15,368,000 | -26,707,000 | -43,072,000 | -46,084,000 | -50,751,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
Assets | -2.8% | 371 | 382 | 414 | 447 | 539 | 607 | 763 | 72.00 | 361 | 355 | 375 | 403 | 429 | 375 | 469 | 512 | 564 | 605 | 409 | 445 | 492 |
Current Assets | -6.9% | 124 | 134 | 162 | 192 | 261 | 353 | 512 | - | 155 | 205 | 250 | 297 | 333 | 293 | 393 | 451 | 498 | 534 | 37.00 | 356 | 426 |
Cash Equivalents | 38.3% | 55.00 | 40.00 | 72.00 | 106 | 188 | 298 | 419 | 29.00 | 87.00 | 94.00 | 91.00 | 121 | 205 | 114 | 81.00 | 93.00 | 105 | 333 | 59.00 | 102 | 178 |
Net PPE | -3.9% | 9.00 | 9.00 | 9.00 | 10.00 | 12.00 | 12.00 | 12.00 | - | 13.00 | 13.00 | 14.00 | 16.00 | 17.00 | 17.00 | 16.00 | 15.00 | 14.00 | 14.00 | 13.00 | 12.00 | 13.00 |
Current Liabilities | -12.5% | 22.00 | 25.00 | 25.00 | 25.00 | 26.00 | 29.00 | 142 | - | 33.00 | 44.00 | 59.00 | 66.00 | 67.00 | 86.00 | 124 | 104 | 107 | 98.00 | 3.00 | 109 | 110 |
Shareholder's Equity | -3.8% | 205 | 213 | 246 | 280 | 371 | 442 | 481 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings | -1.3% | -920 | -909 | -900 | -891 | -876 | -853 | -843 | - | -1,760 | -1,751 | -1,726 | -1,694 | -1,658 | -1,606 | -1,526 | -1,468 | -1,394 | -1,331 | -1,248 | -1,182 | -1,124 |
Additional Paid-In Capital | 0.3% | 1,126 | 1,122 | 1,147 | 1,172 | 1,247 | 1,296 | 1,324 | - | 1,410 | 1,401 | 1,387 | 1,370 | 1,358 | 1,233 | 1,223 | 1,207 | 1,192 | 1,173 | 1,025 | 1,000 | 987 |
Shares Outstanding | 1.0% | 49.00 | 48.00 | 51.00 | 54.00 | 61.00 | 65.00 | 76.00 | 76.00 | 76.00 | 75.00 | 74.00 | 74.00 | 65.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 459 | - | - | - | - | 677 | - | - | - | 882 | - | - | - | 1,280 | - | - | - | 893 |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -19.7% | -1.02 | -0.85 | -2.49 | -12.44 | -11.22 | -124 | -22.14 | -14.73 | -26.07 | -42.43 | -45.45 | -50.11 | -69.86 | -64.92 | -77.03 | -53.35 | -55.10 | -64.35 | -44.62 | -48.03 | -81.19 |
Share Based Compensation | -10.2% | 5.00 | 6.00 | 6.00 | 6.00 | 7.00 | 7.00 | 9.00 | 10.00 | 15.00 | 17.00 | 14.00 | 15.00 | 16.00 | 16.00 | 16.00 | 17.00 | 15.00 | 24.00 | 13.00 | 11.00 | 12.00 |
Cashflow From Investing | 2615.2% | 17.00 | -0.68 | -0.02 | 11.00 | -43.05 | 39.00 | 1,075 | 8.00 | 32.00 | 11.00 | -35.79 | 36.00 | 114 | 52.00 | 67.00 | -176 | 68.00 | 14.00 | -23.66 | -1.30 | -72.16 |
Cashflow From Financing | 94.4% | -1.72 | -30.61 | -31.40 | -80.68 | -56.24 | -35.47 | -722 | 0.00 | -1.45 | 0.00 | -2.29 | 105 | -11.29 | 1.00 | -0.96 | 2.00 | 261 | -1.54 | -0.13 | 4.00 | -1.43 |
Buy Backs | -98.5% | 0.00 | 30.00 | 31.00 | 81.00 | 55.00 | - | 94.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |||
Revenue: | ||||
Total revenue | $ 14,503 | $ 10,417 | ||
Expenses: | ||||
Research and development | [1] | 8,968 | 14,572 | |
Selling, general and administrative | [1] | 16,742 | 19,183 | |
Restructuring and related expenses | [1] | 1,574 | ||
Total expenses | 25,710 | 35,329 | ||
Loss from operations | (11,207) | (24,912) | ||
Interest expense (non-cash) | (629) | (550) | ||
Interest income and other income (expense), net | 1,434 | 2,979 | ||
Loss before income taxes | (10,402) | (22,483) | ||
Provision for income tax expense (benefit) | 1,262 | (395) | ||
Net loss | (11,664) | (22,088) | ||
Other comprehensive loss: | ||||
Net unrealized gain on available-for-sale investments | 24 | 66 | ||
Total comprehensive loss | $ (11,640) | $ (22,022) | ||
Net loss per share: | ||||
Net loss - basic (in dollars per share) | $ (0.24) | $ (0.35) | ||
Net loss - diluted (in dollars per share) | $ (0.24) | $ (0.35) | ||
Shares used to compute net income (loss) per share - basic | 48,283 | 62,934 | ||
Shares used to compute net income (loss) per share - diluted | 48,283 | 62,934 | ||
Viatris collaboration agreement | ||||
Revenue: | ||||
Total revenue | $ 14,503 | $ 10,411 | ||
Collaboration revenue | ||||
Revenue: | ||||
Total revenue | $ 6 | |||
|
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 53,835 | $ 39,545 |
Short-term marketable securities | 46,140 | 62,881 |
Receivables from collaborative arrangements | 14,664 | 17,474 |
Prepaid clinical and development services | 2,086 | 2,038 |
Other prepaid and current assets | 7,569 | 11,603 |
Total current assets | 124,294 | 133,541 |
Property and equipment, net | 8,717 | 9,068 |
Operating lease assets | 35,364 | 36,287 |
Future contingent milestone and royalty assets | 194,200 | 194,200 |
Restricted cash | 836 | 836 |
Other assets | 7,896 | 8,067 |
Total assets | 371,307 | 381,999 |
Current liabilities: | ||
Accounts payable | 1,686 | 1,524 |
Accrued personnel-related expenses | 4,475 | 6,443 |
Accrued clinical and development expenses | 1,399 | 2,246 |
Accrued general and administrative expenses | 2,476 | 2,900 |
Operating lease liabilities | 4,063 | 3,923 |
Tenant improvement payable to subleasee | 6,490 | 6,490 |
Other accrued liabilities | 1,073 | 1,241 |
Total current liabilities | 21,662 | 24,767 |
Long-term operating lease liabilities | 43,840 | 45,236 |
Future royalty payment contingency | 28,417 | 27,788 |
Unrecognized tax benefits | 67,075 | 65,294 |
Other long-term liabilities | 5,445 | 5,919 |
Commitments and contingencies (Note 10) | ||
Shareholders' Equity | ||
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding | ||
Ordinary shares, $0.00001 par value per share: 200,000 shares authorized; 48,566 and 48,091 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | ||
Additional paid-in capital | 1,125,677 | 1,122,164 |
Accumulated other comprehensive loss | (41) | (65) |
Accumulated deficit | (920,768) | (909,104) |
Total shareholders' equity | 204,868 | 212,995 |
Total liabilities and shareholders' equity | $ 371,307 | $ 381,999 |